| A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6 LB Baughn, M Di Liberto, K Wu, PL Toogood, T Louie, R Gottschalk, ... Cancer research 66 (15), 7661-7667, 2006 | 301 | 2006 |
| Overexpression, Purification, and Characterization of the Cloned Metallo-β-Lactamase L1 fromStenotrophomonas maltophilia MW Crowder, TR Walsh, L Banovic, M Pettit, J Spencer Antimicrobial agents and chemotherapy 42 (4), 921-926, 1998 | 234 | 1998 |
| Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder TS Koemans, T Kleefstra, MC Chubak, MH Stone, MRF Reijnders, ... PLoS genetics 13 (10), e1006864, 2017 | 163 | 2017 |
| Targeting TMPRSS2 in SARS-CoV-2 infection LB Baughn, N Sharma, E Elhaik, A Sekulic, AH Bryce, R Fonseca Mayo Clinic Proceedings 95 (9), 1989-1999, 2020 | 132 | 2020 |
| Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation … S Ely, M Di Liberto, R Niesvizky, LB Baughn, HJ Cho, EN Hatada, ... Cancer research 65 (24), 11345-11353, 2005 | 126 | 2005 |
| Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response N Abdallah, SV Rajkumar, P Greipp, P Kapoor, MA Gertz, A Dispenzieri, ... Blood cancer journal 10 (8), 82, 2020 | 121 | 2020 |
| Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model HAF Stessman, LB Baughn, A Sarver, T Xia, R Deshpande, A Mansoor, ... Molecular cancer therapeutics 12 (6), 1140-1150, 2013 | 93 | 2013 |
| Molecular signatures of multiple myeloma progression through single cell RNA-Seq JS Jang, Y Li, AK Mitra, L Bi, A Abyzov, AJ van Wijnen, LB Baughn, ... Blood cancer journal 9 (1), 2, 2019 | 91 | 2019 |
| A simple additive staging system for newly diagnosed multiple myeloma NH Abdallah, M Binder, SV Rajkumar, PT Greipp, P Kapoor, A Dispenzieri, ... Blood cancer journal 12 (1), 21, 2022 | 83 | 2022 |
| Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities N Abdallah, P Greipp, P Kapoor, MA Gertz, A Dispenzieri, LB Baughn, ... Blood Advances 4 (15), 3509-3519, 2020 | 83 | 2020 |
| Glyoxalase II from A. thaliana requires Zn (II) for catalytic activity MW Crowder, MK Maiti, L Banovic, CA Makaroff Febs Letters 418 (3), 351-354, 1997 | 83 | 1997 |
| Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry LB Baughn, K Pearce, D Larson, MY Polley, E Elhaik, M Baird, C Colby, ... Blood cancer journal 8 (10), 96, 2018 | 69 | 2018 |
| Optical genome mapping in acute myeloid leukemia: a multicenter evaluation B Levy, LB Baughn, Y Akkari, S Chartrand, B LaBarge, D Claxton, ... Blood advances 7 (7), 1297-1307, 2023 | 66 | 2023 |
| The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies T Harding, L Baughn, S Kumar, B Van Ness Leukemia 33 (4), 863-883, 2019 | 59 | 2019 |
| Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib HAF Stessman, A Mansoor, F Zhan, S Janz, MA Linden, LB Baughn, ... Leukemia 27 (10), 2075-2077, 2013 | 57 | 2013 |
| Guiding the global evolution of cytogenetic testing for hematologic malignancies YMN Akkari, LB Baughn, AM Dubuc, AC Smith, M Mallo, P Dal Cin, ... Blood, The Journal of the American Society of Hematology 139 (15), 2273-2284, 2022 | 53 | 2022 |
| False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms RL King, ED McPhail, RG Meyer, G Vasmatzis, K Pearce, JB Smadbeck, ... Haematologica 104 (6), e248, 2019 | 53 | 2019 |
| Implications of MYC rearrangements in newly diagnosed multiple myeloma N Abdallah, LB Baughn, SV Rajkumar, P Kapoor, MA Gertz, A Dispenzieri, ... Clinical Cancer Research 26 (24), 6581-6588, 2020 | 51 | 2020 |
| Understanding drug sensitivity and tackling resistance in cancer JW Tyner, F Haderk, A Kumaraswamy, LB Baughn, B Van Ness, S Liu, ... Cancer research 82 (8), 1448-1460, 2022 | 50 | 2022 |
| CDK2 phosphorylation of Smad2 disrupts TGF-β transcriptional regulation in resistant primary bone marrow myeloma cells LB Baughn, M Di Liberto, R Niesvizky, HJ Cho, D Jayabalan, J Lane, ... The Journal of Immunology 182 (4), 1810-1817, 2009 | 50 | 2009 |
